Everything below concerns secretagogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
| Property | Value | Notes |
|---|---|---|
| Purity method | Reversed-phase HPLC | C18 column, UV detection at 214 nm |
| Identity method | Mass spectrometry | Electrospray or MALDI-TOF |
| Solubility | Soluble in water and DMSO | Dissolution may require brief mixing |
| Storage temperature | -20 °C or lower | Desiccated and protected from light |
| Counterion form | Trifluoroacetate or acetate | Affects measured peptide content |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
The positions of president laboratory director and deputy laboratory director are filled by joint action of the chair and vice chair of the executive committee, with the University of California nominating the president and laboratory director and Bechtel nominating the deputy laboratory director. The current LLNS chairman is Norman J. Pattiz, founder and chairman of Westwood One, America's largest radio network, who also currently serves on the board of regents of the University of California. The vice chairman is J. Scott Ogilvie, president of Bechtel Systems & Infrastructure, Inc., who also serves on the board of directors of Bechtel Group, Inc. (BGI) and on the BGI Audit Committee.
=== Incidents involving medical radiation sources === A radioactive contamination incident occurred in 1984 in Ciudad Juárez, Chihuahua, Mexico, originating from a radiation therapy unit illegally purchased by a private medical company and subsequently dismantled for lack of personnel to operate it. The radioactive material, 60Co, ended up in a junkyard, where it was sold to foundries that inadvertently smelted it with other metals and produced about 6,000 tons of contaminated rebar. These were distributed in 17 Mexican states and several cities in the United States. It is estimated that 4,000 people were exposed to radiation as a result of this incident. In the Samut Prakan radiation accident in 2000, a disused radiotherapy head containing a 60Co source was stored at an unsecured location in Bangkok, Thailand and then accidentally sold to scrap collectors. Unaware of the danger, a junkyard employee dismantled the head and extracted the source, which remained unprotected for a period of days at the junkyard. Ten people, including the scrap collectors and workers at the junkyard, were exposed to high levels of radiation and became ill. Three junkyard workers later died of their exposure, which was estimated to be over 6 Gy. Afterward, the source was safely recovered by Thai authorities. In December 2013, a truck carrying a disused 111 TBq 60Co teletherapy source from a hospital in Tijuana to a radioactive waste storage center was hijacked at a gas station near Mexico City. The truck was soon recovered, but the thieves had removed the source from its shielding.
Physiologically, eating is generally triggered by hunger, but there are numerous physical and psychological conditions that can affect appetite and disrupt normal eating patterns. These include depression, food allergies, ingestion of certain chemicals, bulimia, anorexia nervosa, pituitary gland malfunction and other endocrine problems, and numerous other illnesses and eating disorders. A chronic lack of nutritious food can cause various illnesses, and will eventually lead to starvation. While changes in appetite can result from various physical and psychological conditions, including depression, allergies, and anxiety; anorexia and bulimia are specific eating disorders that profoundly impact the entire body. In anorexia nervosa, people restrict their calorie intake out of fear of gaining weight. This malnutrition leads to an unhealthy weight, significantly impacting overall health. Bulimia is characterized by recurrent episodes of binge eating, involving the consumption of a substantial amount of food within a short period. Subsequently, individuals engage in maladaptive behaviors, such as inducing vomiting, excessive physical activity, and using laxatives as compensatory measures. If eating and drinking is not possible, as is often the case when recovering from surgery, alternatives are enteral nutrition and parenteral nutrition.
Sources: en.wikipedia.org
==== Louis Vuitton fashion shows ==== Williams was hand-selected to be the new creative director of menswear at luxury fashion house Louis Vuitton in 2023. In a story with the New York Times about the job and his upcoming debut fashion show with the brand, an unheard song with Pusha T ("Chains & Whips") was teased, although it was not yet revealed as a Clipse song. The three annual spring–summer shows from this point until Let God Sort Em Out's release all featured new Clipse music in their soundtracks, along with other songs. "Chains & Whips" was debuted at the Louis Vuitton's Men's Spring–Summer Show 2024 on June 20, 2023, although Kendrick Lamar's guest verse was not yet included. Pusha T and Malice also walked on the runway in Williams's designs. For the Men's Spring–Summer Show 2025 on June 18, 2024, "The Birds Don't Sing" was previewed for the first time, featuring vocals by John Legend. The Men's Spring–Summer Show 2026 debuted "So Be It Pt. II" on June 24, 2025.
Regular production batches of 238PuO2 particles precipitated as a hydroxide were used to show that large production batches could be effectively 16O2-exchanged on a routine basis. High-fired 238PuO2 microspheres were successfully 16O2-exchanged showing that an exchange will take place regardless of the previous heat treatment history of the 238PuO2. This lowering of the neutron emission rate of PuO2 containing normal oxygen by a factor of five was discovered during the cardiac pacemaker research at Mound Laboratory in 1966, due in part to the Mound Laboratory's experience with production of stable isotopes beginning in 1960. For production of the large heat sources the shielding required would have been prohibitive without this process. Unlike the other three isotopes discussed in this section, 238Pu must be specifically synthesized and is not abundant as a nuclear waste product. At present only Russia has maintained high-volume production, while in the US, no more than 50 g (1.8 oz) were produced in total between 2013 and 2018. The US agencies involved desire to begin the production of the material at a rate of 300 to 400 grams (11 to 14 oz) per year. If this plan is funded, the goal would be to set up automation and scale-up processes in order to produce an average of 1.5 kg (3.3 lb) per year by 2025.
== Function == Urocortin (UCN) II, also known as stresscopin-related peptide, is a 38 amino acid member of the mammalian corticotropin-releasing hormone (CRH) peptide family, which also includes CRH, UCN I, and UCN III. CRH mainly binds to type 1 CRH receptors (CRH1), while UCN II and III bind primarily to type 2 CRH receptors, and UCN I binds to both (CRH2). Each of these hormones has distinctive distribution patterns in the central nervous system and the periphery, suggesting each peptide may have distinct behavioral and physiological effects, although all have been associated with anxiety. In general, agonism of CRH1 receptors is posited to be anxiogenic and agonism of CRH2 receptors is posited to be anxiolytic. Urocortin II has been shown to have anorexigenic effects and hypotensive effects similar to Urocortin, but does not induce secretion of ACTH.
=== Prime Ministers === Prime Minister for Bosnia and Herzegovina (part of Yugoslav Government) Rodoljub Čolaković (7 March 1945 – 27 April 1945) Prime Ministers Rodoljub Čolaković (27 April 1945 – September 1948) Đuro Pucar (September 1948 – March 1953) Chairmen of the Executive Council Đuro Pucar (March 1953 – December 1953) Avdo Humo (December 1953 – 1956) Osman Karabegović (1956–1963) Hasan Brkić (1963–1965) Rudi Kolak (1965–1967) Branko Mikulić (1967–1969) Dragutin Kosovac (1969 – April 1974) Milanko Renovica (April 1974 – 28 April 1982) Seid Maglajlija (28 April 1982 – 28 April 1984) Gojko Ubiparip (28 April 1984 – April 1986) Josip Lovrenović (April 1986 – April 1988) Marko Ceranić (April 1988 – 20 December 1990) Jure Pelivan (20 December 1990 – 8 April 1992)
Sources: en.wikipedia.org
=== Expansion === The idea of expanding the tournament had been suggested as early as 2013 by then-UEFA president Michel Platini, as well as in 2016 by current FIFA president Gianni Infantino. Opponents of the proposal argued that the number of matches played was already at an unacceptable level, that the expansion would dilute the quality of the matches, and that the decision was driven by political rather than sporting concerns, specifically that Infantino was trying to win his election by promising to bring more countries to the World Cup. Starting with the 2026 edition, the World Cup expanded to 48 teams, an increase of 16 teams compared to the previous seven tournaments. As approved by the FIFA Council on March 14, 2023, the teams were split into 12 groups of 4 teams, with the top 2 teams in each group and the 8 best third-place teams progressing to a new round of 32. It was the first expansion and format change since 1998. The total number of matches played increased from 64 to 104, and the number of matches played by teams reaching the semifinals increased from 7 to 8. The tournament lasted 39 days, an increase from the 32 days of the 2014 and 2018 tournaments, and from the 29 days of the 2022 tournament, although each team still played three group matches. The final matchday at club level for players named in the final squads was May 24, 2026; clubs had to release their players by May 25, with exceptions granted to players participating in continental club competition finals up until May 30.
== Applications == BMP has been shown to remain stable, without breaking down, in high-heat pasteurization and sterilization conditions, making it possible for potential use for culinary purposes. Those advocating for the presence of BMP's flavor-enhancing umami taste report that its taste is similar to that of monosodium glutamate. Consequently, BMP possesses potential for large-scale commercialization in the food industry. However, the primary obstacle is the cost of mass production associated with the peptide. Currently, the main modes of production for specific flavor peptides such as BMP are chemical and enzymatic synthesis, both of which involve high production costs.
=== Names === It is often sold as a salt in the form of either codeine sulfate or codeine phosphate in the United States, United Kingdom, and Australia. Codeine hydrochloride is more common worldwide and the citrate, hydroiodide, hydrobromide, tartrate, and other salts are also seen. The chemical name for codeine is morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5α,6α)-
Sources: en.wikipedia.org
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.
Trifluoroacetate and acetate are common in lyophilized peptide preparations. They contribute to the mass of the powder without contributing to the peptide itself. This shifts the true content and can affect results in biological assays.
Hydrolysis and oxidation are the primary pathways. Alkaline conditions accelerate hydrolytic cleavage of the chain. Oxidation most often involves susceptible residues, producing products that appear as earlier or later peaks in chromatographic analysis.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.